Gainesville, United States
Captozyme, founded in 2009 and headquartered in the United States, is at the forefront of innovation in the biotechnology sphere. With a focus on the intersection of health care and gut health, the company leverages its cutting-edge expertise to create novel enzymes and live biotherapeutics. Their guiding principle—"Creating best-in-class enzymes and live biotherapeutics through innovative research and passionate diligence"—captures their dedication to improving standards of care using sound scientific principles.
Establishing its prominence in the Biotechnology, Health Care, Health and Wellness, and Sports sectors, Captozyme not only develops its proprietary products but also collaborates with partners to drive advancements in gut health research. The company's strategic direction is underscored by a $3.40M Series A investment received on March 15, 2017, which highlights investor confidence in its potential. Captozyme represents a promising opportunity for investors seeking to contribute to transformational health care solutions.
